SPOTLIGHT: Genentech licenses Exelixis therapy


Genentech and Exelixis have agreed to a global development pact for XL-518, an MEK-inhibitor for tumors. Exelixis stands to gain up to $40 million in milestones and an upfront fee. Exelixis is responsible for Phase I development. Release